This company listing is no longer active
This company may still be operating, however this listing is no longer active. Find out why through their latest events.
Resumen de acción 73C
Concert Pharmaceuticals, Inc. operates as a clinical stage biopharmaceutical company that develops novel small molecule drugs for the treatment of autoimmune diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Competidores de Concert Pharmaceuticals, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$7.82 |
| 52 Week High | US$7.89 |
| 52 Week Low | US$2.44 |
| Beta | 0.52 |
| 1 Month Change | 2.60% |
| 3 Month Change | 83.35% |
| 1 Year Change | 207.80% |
| 3 Year Change | -6.93% |
| 5 Year Change | -58.53% |
| Change since IPO | -22.69% |
Noticias y actualizaciones recientes
Recent updates
Rentabilidad de los accionistas
| 73C | DE Biotechs | Mercado DE | |
|---|---|---|---|
| 7D | -0.4% | 1.8% | 1.1% |
| 1Y | 207.8% | -23.5% | 1.9% |
Rentabilidad vs. Industria: 73C exceeded the German Biotechs industry which returned 8.3% over the past year.
Rentabilidad vs. Mercado: 73C exceeded the German Market which returned 2.5% over the past year.
Volatilidad de los precios
| 73C volatility | |
|---|---|
| 73C Average Weekly Movement | 9.0% |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.5% |
Precio estable de las acciones: 73C's share price has been volatile over the past 3 months.
Volatilidad a lo largo del tiempo: 73C's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 2006 | 64 | Roger Tung | www.concertpharma.com |
Resumen de fundamentos de Concert Pharmaceuticals, Inc.
| Estadísticas fundamentales de 73C | |
|---|---|
| Capitalización bursátil | €487.33m |
| Beneficios(TTM) | -€118.56m |
| Ingresos (TTM) | €29.99m |
16.3x
Ratio precio-ventas (PS)-4.1x
Ratio precio-beneficio (PE)¿Está 73C sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de 73C | |
|---|---|
| Ingresos | US$32.04m |
| Coste de los ingresos | US$102.70m |
| Beneficio bruto | -US$70.66m |
| Otros gastos | US$56.02m |
| Beneficios | -US$126.68m |
Últimos beneficios comunicados
Sep 30, 2022
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | -2.04 |
| Margen bruto | -220.53% |
| Margen de beneficio neto | -395.36% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado 73C a largo plazo?
Ver rendimiento histórico y comparativa